Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Open accessAbstract
The discovery of ketamine's rapid and robust antidepressant effects opened a window into a new generation of antidepressants. Multiple controlled trials and open‐label studies have demonstrated these effects across a variety of patient populations known to often achieve little to no response from traditional antidepressants. Ketamine has been generally well tolerated across patient groups, with transient mild‐to‐moderate adverse effects during infusion. However, the optimal dosing and route of administration and the safety of chronic treatment are not fully known. This review summarizes the clinical effects of ketamine and its neurobiological underpinnings and mechanisms of action, which may provide insight into the neurobiology of depression, relevant biomarkers, and treatment targets. Moreover, we offer suggestions for future research that may continue to advance the field forward and ultimately improve the psychopharmacologic interventions available for those individuals struggling with depressive and trauma‐related disorders.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Data from human studies, including the authors' group, show ketamine's rapid antidepressant effects even in individuals with treatment-resistant depression.
“data from human studies, including our group [103], show ketamine's rapid antidepressant effects even in individuals with treatment-resistant depression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 88 · Cited by 121
Research works printed but not linked: 2
- [64]Homayoun H Moghaddam B NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons J Neurosci 2007 27 11496 11500 17959792 PMC2954603
- [89]Salvadore G An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression Int J Neuropsychopharmacol 2012 15 1063 1072 22040773 PMC3342437
- Authors
- Abdallah, C. G., Averill, L. A., & Krystal, J. H.
- Affiliations
- United States Department of Veterans Affairs (US)
- Corresponding author
- Abdallah, Chadi G.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2015-02-27
- Volume
- 1344
- Issue
- 1
- Pages
- 66-77
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- PMC
- PMC4412785
- OpenAlex
- W2108040321
- Cited by
- 121
- References
- 88
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 9 · 2021: 9 · 2020: 13 · 2019: 14 · 2018: 13 · 2017: 13 · 2016: 21 · 2015: 13
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of the New York Academy of Sciences (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (MH101498)
- Brain and Behavior Research Foundation
- U.S. Department of Veterans Affairs
- U.S. Department of Health and Human Services (RR024139)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, rapid-acting antidepressants, depression, antidepressant mechanism, neurobiology of depression, biomarkers, treatment goals, trauma-related disorders, adverse effects
- MeSH terms
- Animals, Depression, Humans, Ketamine, Wounds and Injuries, Biomarkers, Antidepressive Agents, Second-Generation, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
